September 21, 2020 -- Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.
Under the evaluation agreement, Takeda will evaluate Elektrofi's microparticle-based formulation technology, Elektroject. Elektroject uses proprietary technology to generate highly concentrated, small-volume injections of monoclonal antibodies, therapeutic proteins, and other biologics.
Takeda will investigate the storage stability and properties of microparticles created by Elektroject, as well as the stability and formulations with high concentrations of a target protein. Terms of the agreement were not disclosed.